FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226440498> ?p ?o ?g. }

• W4226440498 endingPage "170" @default.
• W4226440498 startingPage "161" @default.
• W4226440498 abstract "Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan based on CheckMate 142. Presented are results of nivolumab plus low-dose ipilimumab in the first-line therapy cohort from the phase II CheckMate 142 study.Patients with no prior treatment in the metastatic setting for MSI-H/dMMR CRC were treated with nivolumab every 2 weeks plus low-dose ipilimumab every 6 weeks until disease progression. The primary end point was objective response rate (investigator assessment; RECIST v1.1).Median age of treated patients was 66 years (N = 45). Median follow-up was 29.0 months. Objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.5 to 93.5), respectively, with 13% complete response rate. Median duration of response was not reached; 74% of responders had ongoing responses at data cutoff. Median progression-free survival and median overall survival were not reached with minimum follow-up of 24.2 months (24-month rates, 74% and 79%, respectively). Clinical benefit was observed regardless of baseline demographic and tumor characteristics, including BRAF or KRAS mutation status. In a post hoc analysis, of 14 patients who discontinued treatment and did not receive subsequent therapy, 10 remained progression-free. Patient-reported outcomes were stable over the treatment period. Grade 3-4 treatment-related adverse events occurred in 22% of patients; 13% discontinued because of any-grade treatment-related adverse events.Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted." @default.
• W4226440498 created "2022-05-05" @default.
• W4226440498 creator A5003827387 @default.
• W4226440498 creator A5009733496 @default.
• W4226440498 creator A5010469485 @default.
• W4226440498 creator A5017619486 @default.
• W4226440498 creator A5022500195 @default.
• W4226440498 creator A5030715123 @default.
• W4226440498 creator A5031976935 @default.
• W4226440498 creator A5034884991 @default.
• W4226440498 creator A5045441776 @default.
• W4226440498 creator A5051613962 @default.
• W4226440498 creator A5060058983 @default.
• W4226440498 creator A5065671989 @default.
• W4226440498 creator A5076874377 @default.
• W4226440498 creator A5078616360 @default.
• W4226440498 creator A5082449165 @default.
• W4226440498 creator A5090464803 @default.
• W4226440498 creator A5090645179 @default.
• W4226440498 date "2022-01-10" @default.
• W4226440498 modified "2023-10-17" @default.
• W4226440498 title "First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study" @default.
• W4226440498 cites W1849671624 @default.
• W4226440498 cites W1947168884 @default.
• W4226440498 cites W2019607817 @default.
• W4226440498 cites W2076668534 @default.
• W4226440498 cites W2098428600 @default.
• W4226440498 cites W2128035403 @default.
• W4226440498 cites W2143743735 @default.
• W4226440498 cites W2159064822 @default.
• W4226440498 cites W2166662937 @default.
• W4226440498 cites W2167571044 @default.
• W4226440498 cites W2418354692 @default.
• W4226440498 cites W2473786944 @default.
• W4226440498 cites W2560704457 @default.
• W4226440498 cites W2592701528 @default.
• W4226440498 cites W2594373254 @default.
• W4226440498 cites W2622499649 @default.
• W4226440498 cites W2736728025 @default.
• W4226440498 cites W2737084095 @default.
• W4226440498 cites W2739132742 @default.
• W4226440498 cites W2760877680 @default.
• W4226440498 cites W2767221986 @default.
• W4226440498 cites W2784868445 @default.
• W4226440498 cites W2786816161 @default.
• W4226440498 cites W2802554884 @default.
• W4226440498 cites W2889646458 @default.
• W4226440498 cites W2891756618 @default.
• W4226440498 cites W2914573001 @default.
• W4226440498 cites W2921349646 @default.
• W4226440498 cites W2983284890 @default.
• W4226440498 cites W3110528877 @default.
• W4226440498 doi "https://doi.org/10.1200/jco.21.01015" @default.
• W4226440498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34637336" @default.
• W4226440498 hasPublicationYear "2022" @default.
• W4226440498 type Work @default.
• W4226440498 citedByCount "215" @default.
• W4226440498 countsByYear W42264404982021 @default.
• W4226440498 countsByYear W42264404982022 @default.
• W4226440498 countsByYear W42264404982023 @default.
• W4226440498 crossrefType "journal-article" @default.
• W4226440498 hasAuthorship W4226440498A5003827387 @default.
• W4226440498 hasAuthorship W4226440498A5009733496 @default.
• W4226440498 hasAuthorship W4226440498A5010469485 @default.
• W4226440498 hasAuthorship W4226440498A5017619486 @default.
• W4226440498 hasAuthorship W4226440498A5022500195 @default.
• W4226440498 hasAuthorship W4226440498A5030715123 @default.
• W4226440498 hasAuthorship W4226440498A5031976935 @default.
• W4226440498 hasAuthorship W4226440498A5034884991 @default.
• W4226440498 hasAuthorship W4226440498A5045441776 @default.
• W4226440498 hasAuthorship W4226440498A5051613962 @default.
• W4226440498 hasAuthorship W4226440498A5060058983 @default.
• W4226440498 hasAuthorship W4226440498A5065671989 @default.
• W4226440498 hasAuthorship W4226440498A5076874377 @default.
• W4226440498 hasAuthorship W4226440498A5078616360 @default.
• W4226440498 hasAuthorship W4226440498A5082449165 @default.
• W4226440498 hasAuthorship W4226440498A5090464803 @default.
• W4226440498 hasAuthorship W4226440498A5090645179 @default.
• W4226440498 hasConcept C104317684 @default.
• W4226440498 hasConcept C121608353 @default.
• W4226440498 hasConcept C126322002 @default.
• W4226440498 hasConcept C141071460 @default.
• W4226440498 hasConcept C143998085 @default.
• W4226440498 hasConcept C180754005 @default.
• W4226440498 hasConcept C185592680 @default.
• W4226440498 hasConcept C197934379 @default.
• W4226440498 hasConcept C203092338 @default.
• W4226440498 hasConcept C2776694085 @default.
• W4226440498 hasConcept C2777701055 @default.
• W4226440498 hasConcept C2779767149 @default.
• W4226440498 hasConcept C2779984678 @default.
• W4226440498 hasConcept C2780030458 @default.
• W4226440498 hasConcept C2780259306 @default.
• W4226440498 hasConcept C2780739268 @default.
• W4226440498 hasConcept C2780962732 @default.
• W4226440498 hasConcept C2781187634 @default.
• W4226440498 hasConcept C2781433595 @default.
• W4226440498 hasConcept C31760486 @default.

• next